OncologyTube Blog

BRCA1, BRCA2 or PALB2 in Pancreatic Cancer

Jul 13, 2022 11:34:14 AM / by Stephanie posted in Penn Medicine


Read More

DetermaIO algorithm and qPCR assay

Jul 12, 2022 3:02:17 PM / by Stephanie posted in Oncocyte


Read More

HER3 and Seribantumab and the CRESTONE Data

Jul 12, 2022 12:36:09 PM / by Stephanie posted in Atrium Health


Read More

ASCO Top 3 Trending Interviews - June 5th, 2022 - eNewsletter Blog

Jul 1, 2022 1:09:17 PM / by Stephanie posted in ASCO22, COSMIC-021, QUILT-3.032, S1800A Trial


Oncology Update, ASCO 2022 Top 3 Trending Interviews
Read More

Top Trending Oncology News Week Ending June 19, 2022

Jun 20, 2022 4:24:13 PM / by Stephanie posted in ASCO22


Phase 3 Real-world Effectiveness Of G-CSF In Pts with BC

📺 Click To View

🔊Click To Listen


This is a phase 3 multi-center randomized controlled experiment. In Phase 3, 222 individuals are expected to be enrolled.

The chemotherapy in this study will consist of docetaxel, doxorubicin, and cyclophosphamide (TAC). These are some of the most active and widely used chemotherapeutic medicines for treating patients with breast cancer. TAC chemotherapy, in particular, has been used as an adjuvant treatment for HER2 negative early breast cancer patients with node positive illness, as well as node negative breast cancer patients with a high risk of recurrence.

Plinabulin is a new small chemical being researched to treat chemotherapy-induced neutropenia. Plurabulin will be given in a single dosage per cycle by IV infusion on the same day as (about 1 hour after) chemotherapy (TAC). Plinabulin is being researched to see if it may be used instead of G-CSF, pegfilgrastim, to avoid chemotherapy-induced neutropenia.

This experiment will be double-blind, with around 222 breast cancer patients expected to participate. Patients are allocated to one of the treatment arms at random, with 111 patients in each arm, with the arm designation and planned intervention as follows:

TAC + pegfilgrastim (6.0 mg) + placebo matching plinabulin in arm 1.

TAC + pegfilgrastim (6.0 mg) + plinabulin (Arm 2) (40 mg).

TAC (or TC for Cycles 2–4) will be delivered IV on Day 1 every 21 days for Cycles 1–4. Patients will be given a single dose of plinabulin or placebo IV over 30 minutes (5 minutes) in a double-blind fashion, 30 minutes after the end of the TAC (or TC for Cycles 2 to 4). All patients will receive a single dose of pegfilgrastim on Day 2 of each cycle (24 hours after completing chemotherapy) (6.0 mg).

Long-term safety follow-up will be undertaken on all subjects approximately every 6 months up to 5 years through patient interactions via phone calls, mail, or electronic methods; or medical record reviews.                                                            

Read More